News & Updates

Show Multimedia Only

First-line NALIRIFOX regimen ups survival in metastatic pancreatic cancer

14 Feb 2023 by

The use of liposomal irinotecan in combination with 5-fluorouracil, leucovorin, and oxaliplatin (NALIRIFOX regimen) significantly improved overall survival (OS) and progression-free survival (PFS) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) compared with gemcitabine plus nab-paclitaxel (Gem+NabP) in the first-line setting, according to the NAPOLI-3* trial presented at the ASCO GI 2023.

First-line NALIRIFOX regimen ups survival in metastatic pancreatic cancer

14 Feb 2023

Early antibiotics does not prevent infection in hospitalized cirrhosis patients

13 Feb 2023 by

Antibiotics are usually prescribed by physicians to patients hospitalized with decompensated cirrhosis even without an infection diagnosis, according to a UK study. However, this practice has neither reduced the overall risk of hospital-acquired infections (HAI) nor improved survival.

Early antibiotics does not prevent infection in hospitalized cirrhosis patients

13 Feb 2023

Novel KRAS G12C inhibitor shows promising antitumour activity in mutated pancreatic cancer

11 Feb 2023

The investigational KRAS G12C inhibitor sotorasib appears to be active against previously treated KRAS p.G12C–mutated advanced pancreatic cancer while having an acceptable safety profile, according to the results of a phase I/II trial.

Novel KRAS G12C inhibitor shows promising antitumour activity in mutated pancreatic cancer

11 Feb 2023

Herbal combo regimen shows promise for ulcerative colitis

10 Feb 2023 by

A combination regimen comprising two herbal extracts – curcumin and Qing Dai (QD) – have shown potential in the treatment of active* ulcerative colitis (UC), according to two trials from Israel presented at Crohn’s & Colitis Congress (CCC) 2023.

Herbal combo regimen shows promise for ulcerative colitis

10 Feb 2023

Alcohol drinking blamed for rise in colorectal cancer cases among young adults

10 Feb 2023

Consumption of alcohol appears to be a risk factor for early-onset colorectal cancer and has driven an increase in the incidence of colorectal cancer among young adults, as shown in a study.

Alcohol drinking blamed for rise in colorectal cancer cases among young adults

10 Feb 2023

Novel device safely delivers therapeutic compound in the colon

09 Feb 2023 by

Use of a novel drug delivery system (DDS) to deliver a therapeutic compound in the colon has been successful, achieving the intended function with no serious adverse events, reports a study presented at the recent Crohn’s & Colitis Congress (CCC 2023).

Novel device safely delivers therapeutic compound in the colon

09 Feb 2023

Gluten-free diet adherence suboptimal in individuals with celiac disease–IBD overlap

09 Feb 2023 by

Adherence to gluten-free diet (GFD) in individuals with celiac disease and inflammatory bowel disease (IBD) appears to be low, according to a study.

Gluten-free diet adherence suboptimal in individuals with celiac disease–IBD overlap

09 Feb 2023

Severe disease, short induction course up UC flare risk after tofacitinib dose de-escalation

08 Feb 2023 by

Ulcerative colitis (UC) flare at 12 months has occurred in more than half of UC patients with tofacitinib dose de-escalation, according to a study presented at the recent Crohn’s & Colitis Congress (CCC 2023). Factors associated with UC flare following de-escalation are shorter induction course (<16 weeks) and active disease at 6 months of tofacitinib.

Severe disease, short induction course up UC flare risk after tofacitinib dose de-escalation

08 Feb 2023

MAFLD drives up risk of chronic kidney disease in diabetic individuals

08 Feb 2023

Among adults with type 2 diabetes, the risk of developing chronic kidney disease is high in the presence of metabolic dysfunction-associated fatty liver disease (MAFLD), as shown in a study.

MAFLD drives up risk of chronic kidney disease in diabetic individuals

08 Feb 2023

Early response to vedolizumab linked to week 52 remission in ulcerative colitis

07 Feb 2023

Patients with ulcerative colitis (UC) who achieve early partial Mayo score (PMS) remission with vedolizumab are more likely to attain week 52 remission than delayed responders, suggests a study.

Early response to vedolizumab linked to week 52 remission in ulcerative colitis

07 Feb 2023

News & Updates

Showing Gastroenterology articles

Showing

Specialty:

First-line NALIRIFOX regimen ups survival in metastatic pancreatic cancer

First-line NALIRIFOX regimen ups survival in metastatic pancreatic cancer

Early antibiotics does not prevent infection in hospitalized cirrhosis patients

Early antibiotics does not prevent infection in hospitalized cirrhosis patients

Novel KRAS G12C inhibitor shows promising antitumour activity in mutated pancreatic cancer

Novel KRAS G12C inhibitor shows promising antitumour activity in mutated pancreatic cancer

Herbal combo regimen shows promise for ulcerative colitis

Herbal combo regimen shows promise for ulcerative colitis

Alcohol drinking blamed for rise in colorectal cancer cases among young adults

Alcohol drinking blamed for rise in colorectal cancer cases among young adults

Novel device safely delivers therapeutic compound in the colon

Novel device safely delivers therapeutic compound in the colon

Gluten-free diet adherence suboptimal in individuals with celiac disease–IBD overlap

Gluten-free diet adherence suboptimal in individuals with celiac disease–IBD overlap

Severe disease, short induction course up UC flare risk after tofacitinib dose de-escalation

Severe disease, short induction course up UC flare risk after tofacitinib dose de-escalation

MAFLD drives up risk of chronic kidney disease in diabetic individuals

MAFLD drives up risk of chronic kidney disease in diabetic individuals

Early response to vedolizumab linked to week 52 remission in ulcerative colitis

Early response to vedolizumab linked to week 52 remission in ulcerative colitis